CooperCompanies retains CooperSurgical and lifts buyback to $3bn
CooperCompanies has concluded a strategic review that began in December 2025, announcing it will retain its CooperSurgical fertility and women's healthcare division rather than proceed with a sale. The board also expanded its share repurchase authorisation from $2 billion to $3 billion, signalling confidence in the company's intrinsic value at a time when it believes the market is underpricing its assets.
The Nasdaq-listed medical device group said its board evaluated a sale of CooperSurgical through "a thorough evaluation of strategic alternatives involving numerous parties" but ultimately concluded unanimously that no offer received reflected fair value. Board chair Colleen Jay attributed the valuation shortfall to two transient factors: the recent entry of a competitor into the non-hormonal IUD market, and the financial overhang from a recently settled fertility litigation matter. The board judged that both pressures were temporary and that offers received did not reflect the division's longer-term prospects.
Why the deal fell apart
The non-hormonal IUD competitive dynamic is a reference to a shifting landscape in contraception, where several players have been pursuing alternatives to hormonal devices, putting near-term pricing pressure on CooperSurgical's women's health portfolio. Combined with litigation costs that would have been visible to any acquirer conducting due diligence, the company argues it faced a structural discount in negotiations that does not reflect normalised earnings power.
CooperCompanies repurchased $445 million of its own shares during the current fiscal year ahead of this announcement, and the newly authorised $3 billion envelope gives management sustained flexibility to continue buybacks as free cash flow accumulates. President and chief executive Al White framed the strategic review as having identified "meaningful opportunities to enhance execution, sharpen strategic focus and accelerate innovation," though specific financial targets or margin improvement goals were not disclosed in the release.
Operational priorities and market context
On the operational side, the company outlined four workstreams: expanding CooperVision's global sales and marketing organisation; launching cost reduction and efficiency programmes; revising inventory and logistics processes to improve customer service; and accelerating new product introductions for the contact lens market. The company also announced that its Vision Centre, CooperVision's new global R&D innovation hub, is scheduled to open on 23 September 2026.
CooperVision competes in a contact lens market that remains structurally resilient, driven by myopia management and the ongoing shift toward daily disposable silicone hydrogel lenses. The company positions itself as a leading player in that segment. CooperSurgical, meanwhile, operates in the fertility services and assisted reproductive technology supply chain, a sector that has attracted consistent investor interest globally as birth-rate policy and IVF access expand in several markets.
Two new independent directors with medical device CEO experience were added to the board during the review, a governance step the company attributed to constructive engagement with shareholders. The addition of operationally experienced directors is a common concession when activist shareholders or large institutional holders push for strategic change and a sale process does not materialise.
CooperCompanies said it will provide further updates on its operational initiatives, capital allocation priorities, and growth investments in coming quarters. Investors will be watching for evidence that the organic growth agenda at CooperVision and the efficiency drive at CooperSurgical can deliver earnings momentum sufficient to close the perceived valuation gap the board cited as the reason no sale was completed.